Published: Apr 18, 2024 By Tristan Manalac
Pictured: FDA’s signage outside its office in Washington, DC/iStock, JHVEPhoto
The FDA on Tuesday approved Alvotech and Teva Pharmaceuticals’ Selarsdi (astekinumab-aekn), a biosimilar to Johnson & Johnson’s blockbuster…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
